10-K: Corcept 2025 Annual: Relacorilant FDA Setback, Oncology Progress

Corcept Therapeutics reports strong 2025 revenue growth driven by Korlym sales, despite an FDA Complete Response Letter for relacorilant in hypercortisolism, while oncology programs show promising advancements.

Summary

• Net product revenue for 2025 was $761.4 million, an increase from $675.0 million in 2024, driven by a 37.0% increase in sales volume, partially offset by a 17.7% decrease in average price due to higher sales of the authorized generic version of Korlym.
• The FDA issued a Complete Response Letter (CRL) for relacorilant as a treatment for endogenous hypercortisolism, requesting additional evidence of efficacy.
• Submitted a New Drug Application (NDA) to the FDA in July 2025 for relacorilant plus nab-paclitaxel for platinum-resistant ovarian cancer, with a Prescription Drug User Fee Act (PDUFA) date of July 11, 2026.
• The Phase 3 ROSELLA trial for relacorilant in platinum-resistant ovarian cancer met its dual primary endpoints, showing a 30% reduction in risk of disease progression (PFS) and a 35% reduction in risk of death (OS).
• The Phase 2 DAZALS trial for dazucorilant in ALS did not meet its primary endpoint (change in ALS Functional Rating Scale-Revised) but observed an 84% reduction in early death at week 24 (300 mg dose) and continued survival benefit at one year.
• Research and development expense increased to $254.9 million in 2025 from $246.9 million in 2024, while selling, general and administrative expense rose to $448.7 million from $280.3 million.
• Net income decreased to $99.652 million in 2025 from $141.209 million in 2024.
• Cash, cash equivalents, and marketable securities totaled $532.4 million as of December 31, 2025, down from $603.2 million in 2024.
• Transitioned substantially all specialty pharmacy services from Optime Care, Inc. to Curant Health Georgia, LLC in the fourth quarter of 2025, with full transition expected after the first quarter of 2026.
• An appellate court affirmed a District Court's ruling that Teva's generic version of Korlym does not infringe Corcept's patents, following Teva's launch of its generic product in January 2024.
• Ongoing legal proceedings include a securities class action, antitrust litigation, and a records subpoena from the United States Attorney's Office for the District of New Jersey.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a mixed filing. While strong revenue growth and positive oncology trial results are encouraging, the FDA's CRL for relacorilant in hypercortisolism and the ongoing generic competition for Korlym introduce significant regulatory and market uncertainties.

Positives

• Net product revenue increased by 12.8% to $761.4 million in 2025, driven by a 37.0% increase in sales volume.
• The Phase 3 ROSELLA trial for relacorilant in platinum-resistant ovarian cancer met its dual primary endpoints, demonstrating a clinically and statistically significant 30% reduction in risk of disease progression and a 35% reduction in the risk of death.
• Relacorilant in combination with nab-paclitaxel was well-tolerated in the ROSELLA trial, without increasing the safety burden of patients.
• The Phase 2 DAZALS trial for dazucorilant in ALS showed a statistically significant 84% reduction in the risk of early death at week 24 (300 mg dose) and a continued survival benefit at the one-year mark.
• Dazucorilant has been granted Fast Track Designation and orphan drug status by the FDA for the treatment of ALS in the United States.
• Relacorilant has orphan drug designation for hypercortisolism in the US (seven years of exclusive marketing rights if approved) and the EU (ten years of exclusive marketing rights if approved).
• Relacorilant has also been designated an orphan drug in the EU for the treatment of ovarian and pancreatic cancers.
• The MONARCH Phase 2b trial for miricorilant in MASH has completed enrollment in both patient cohorts.
• Maintains a strong intellectual property portfolio with U.S. and foreign patents covering selective cortisol modulators and their methods of use, with expiration dates ranging from 2028 to 2043.
• Management concluded that internal control over financial reporting was effective as of December 31, 2025.

Negatives

• The FDA issued a Complete Response Letter (CRL) for relacorilant in hypercortisolism, declining approval and requiring additional evidence of efficacy.
• The average price of products decreased by 17.7% in 2025, primarily due to higher sales volume from the authorized generic version of Korlym.
• Net income decreased to $99.652 million in 2025 from $141.209 million in 2024, primarily due to higher operating expenses.
• Cash, cash equivalents, and marketable securities decreased by $70.8 million, from $603.2 million in 2024 to $532.4 million in 2025.
• An appellate court affirmed the District Court's ruling that Teva's generic version of Korlym does not infringe Corcept's patents, following Teva's launch of its generic product in January 2024.
• The Phase 2 DAZALS trial for dazucorilant in ALS did not meet its primary endpoint of change from baseline in the ALS Functional Rating Scale-Revised (ALSFRS-R).
• Ongoing antitrust litigation filed by Teva and Aetna Inc. against Corcept and Optime Care, Inc. poses legal and financial risks.
• Received a records subpoena from the United States Attorney's Office for the District of New Jersey in November 2021, investigating potential criminal or civil violations related to Korlym sales and promotion.
• The primary specialty pharmacy vendor (Optime) was unable to fully meet demand for products in 2025, which impacted revenue.

Risks

• Failure to generate sufficient revenue from the sale of products would harm financial results and likely cause the stock price to decline.
• The availability of generic versions of Korlym could adversely affect business, results of operations, and financial position.
• Public perception of mifepristone or legislation limiting or barring its distribution or use for termination of early pregnancy may limit the ability to sell current products.
• New laws, government regulations, or changes to existing laws and regulations could make it difficult or impossible to obtain acceptable prices or adequate insurance coverage and reimbursement for products, including impacts from the Inflation Reduction Act of 2022 and the One Big Beautiful Bill Act of 2025.
• Vendors perform many activities necessary for clinical trials, and their failure to perform or meet timelines may prevent or delay product candidate approval.
• Efforts to discover, develop, and commercialize product candidates may not succeed, as clinical drug development is lengthy, expensive, and often unsuccessful, with early study results not always predictive of later trials.
• Regulatory authorities may not agree that product candidates' clinical trial results demonstrate safety and efficacy, leading to failure to obtain or maintain regulatory approvals.
• Inability to secure, maintain, or effectively assert patent protection for the composition, manufacture, or methods of use of proprietary selective cortisol modulators and for the use of products to treat hypercortisolism.
• The price of common stock fluctuates widely and is likely to continue to do so, limiting opportunities for investors to sell shares.
• Stock price may decline if financial performance does not meet public guidance, research analyst estimates, or other investor expectations.
• Actions by the federal government of the United States, including funding reductions, tariffs, and regulatory uncertainty, may adversely affect the business.
• Reliance on information technology; a breakdown or breach of systems or failure to protect confidential information could interrupt business operations and subject the company to liability.
• Need to increase the size of the organization and potential difficulties in managing growth.
• Loss of key personnel or inability to attract more skilled personnel.
• Subject to regulations and other legal obligations relating to drug development and commercialization, publicly traded securities, and individual privacy and data protection, with compliance being complex and costly.
• Products and product candidates may cause undesirable side effects that halt clinical development, prevent regulatory approval, limit commercial potential, or cause significant liability.
• May need additional capital to fund operations or for strategic reasons, and such capital may not be available on acceptable terms or at all.
• Interim results from clinical trials and preclinical studies may change as more patient data become available and are subject to audit and verification procedures.
• Changes in federal, state, and local tax laws may reduce net earnings.
• Subject to short selling strategies that may drive down the market price of common stock and increase its volatility.
• Any acquisition of Corcept shares through the stock repurchase program or option exercises will reduce cash reserves.
• Anti-takeover provisions in the charter and bylaws and under Delaware law may make an acquisition or change in management more expensive or difficult.
• Officers, directors, and principal stockholders, acting as a group, could significantly influence corporate actions.

Future Outlook

Expects research and development expense to be higher in 2026 as clinical programs advance and new clinical trials are initiated. Selling, general and administrative expense is also anticipated to be higher in 2026 due to increased commercial and administrative activities. The Inflation Reduction Act's inflation rebate provision is expected to limit revenue from Medicare patients and may materially reduce profits in 2026 and beyond. A pivotal Phase 3 trial for dazucorilant in ALS is expected to start in 2026, following completion of a dose titration study.

Management Comments

• "We are working with the FDA to determine relacorilant's optimal path to approval."
• "Our policy is that no patient with hypercortisolism will be denied access to our Products for financial reasons."
• "We expect our research and development expense to be higher in 2026 than in 2025 as our clinical programs advance and we initiate new clinical trials."
• "We expect our selling, general and administrative expense to be higher in 2026 than in 2025 due to increased commercial and administrative activities to support our increased sales and marketing efforts."
• "Based on our current plans and expectations, we expect to fund our operations and planned research and development activities over the next 12 months and beyond without needing to raise additional funds, although we may choose to raise additional funds for other reasons."

Industry Context

StockSavvy.ai notes that the FDA's Complete Response Letter for relacorilant in hypercortisolism highlights the increasing scrutiny and high bar for efficacy in rare disease indications, potentially impacting other companies in the endocrinology space. The strong oncology trial results for relacorilant, particularly in platinum-resistant ovarian cancer, position Corcept favorably against competitors in a challenging cancer treatment area, especially given the well-tolerated safety profile. The ongoing legal challenges regarding generic competition and antitrust issues reflect broader industry trends of intense patent defense and market access disputes in the pharmaceutical sector.

Comparison to Industry Standards

• Relacorilant's 30% reduction in risk of disease progression (PFS) and 35% reduction in risk of death (OS) in platinum-resistant ovarian cancer (ROSELLA trial) are significant, especially compared to nab-paclitaxel monotherapy. This could be a strong competitive advantage against existing treatments like bevacizumab, which is the approved standard of care, or other chemotherapies.
• The 84% reduction in risk of death for dazucorilant (300 mg dose) in ALS patients, while an exploratory endpoint, is a notable survival benefit in a disease with limited effective treatments, potentially positioning it favorably against current ALS therapies like Riluzole or Edaravone, which offer more modest benefits.
• The FDA's CRL for relacorilant in hypercortisolism, despite positive GRACE and GRADIENT trial results, indicates a higher efficacy bar than anticipated, potentially setting a precedent for other orphan drug applications in endocrinology. This contrasts with the approval pathways for competitors like Recordati's Signifor and Isturisa, or Xeris Biopharma's Recorlev, which have already secured approval for Cushing's syndrome.

Corporate Governance

Legal Proceedings

• **Purported Securities Class Action (Allegheny County Employees Retirement System v. Corcept Therapeutics Incorporated, et al.)**: Filed February 20, 2026, alleging violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5, claiming false and misleading statements regarding the relacorilant NDA for hypercortisolism. The putative class period is October 31, 2024, to December 30, 2025, seeking damages, attorneys' fees, and costs.
• **Teva Patent Litigation**: Corcept filed a lawsuit in March 2018 against Teva for infringement of Korlym patents. On December 29, 2023, the District Court ruled Teva's generic product would not infringe. On February 19, 2026, the appellate court affirmed the District Court's ruling of non-infringement.
• **Antitrust Litigation (Teva Pharmaceuticals USA, Inc. v. Corcept Therapeutics, Inc., et al.)**: Filed June 13, 2024, by Teva against Corcept and Optime Care, Inc., alleging violations of federal and state antitrust and unfair business practices laws. The District Court granted in part and denied in part a motion to dismiss on September 12, 2025. Teva subsequently filed Second and Third Amended Complaints, and the case is scheduled for trial in March 2027.
• **Antitrust Litigation (Aetna Inc., Health Care Service Corporation, Humana Inc. and Molina Healthcare Inc. vs. Corcept Therapeutics, Inc.)**: Filed February 10, 2025, in Alameda County Superior Court, with allegations substantially similar to the Teva Antitrust Litigation. The case was remanded back to state court on September 18, 2025.
• **Shareholder Derivative Complaints (Williams and Jeweltex Complaints)**: Filed September 2019 and December 2019, respectively, alleging breach of fiduciary duty, Section 14(a) violation, insider selling, misappropriation of insider information, and waste of corporate assets. These complaints were consolidated and later dismissed on October 30, 2025.
• **Shareholder Derivative Complaint (Joel B. Ritchie v. G. Leonard Baker, et al.)**: Filed January 2022, alleging a single cause of action for breach of fiduciary duty. A motion to dismiss this complaint was granted on July 22, 2025.
• **November 2021 Records Subpoena (NJ USAO)**: Received a records subpoena from the United States Attorney's Office for the District of New Jersey in November 2021, seeking documents related to the sale and promotion of Korlym, relationships with healthcare professionals, and prior authorizations and reimbursement for Korlym. The company is cooperating with the investigation and is not currently considered a defendant.

Stakeholder Impact

• **Shareholders**: Potential negative impact from stock price volatility due to the FDA's CRL for relacorilant, the unfavorable outcome of the Teva patent litigation, and ongoing antitrust litigation. The stock repurchase program could provide some support by reducing share count.
• **Patients**: Continued access to Korlym and its authorized generic. Potential for new treatment options for hypercortisolism (relacorilant), ovarian cancer (relacorilant), ALS (dazucorilant), and MASH (miricorilant) in the future. Patient support programs aim to ensure access regardless of financial ability.
• **Employees**: Increased research and development and selling, general and administrative expenses indicate continued investment in growth and potential hiring. The company offers competitive compensation and equity grants to attract and retain talent.
• **Customers (Physicians/Payors)**: Ongoing educational programs for physicians regarding hypercortisolism. The transition to Curant Health Georgia, LLC as the new specialty pharmacy vendor aims to provide streamlined distribution and patient support services.
• **Suppliers/Vendors**: The transition from Optime Care, Inc. to Curant Health Georgia, LLC impacts vendor relationships. Continued reliance on contract manufacturers for active pharmaceutical ingredients and product candidates.
• **Creditors**: A solid cash position and ongoing revenue generation support the company's ability to meet financial obligations, reducing immediate creditor risk.

Next Steps

• Work with the FDA to determine relacorilant's optimal path to approval for hypercortisolism.
• Complete the transition of specialty pharmacy services from Optime to Curant after the first quarter of 2026.
• Initiate a Phase 2 trial (STELLA) in 50 patients with cervical cancer in the first quarter of 2026.
• Start a pivotal Phase 3 trial for dazucorilant in ALS in 2026, following completion of a dose titration study.
• Await the FDA PDUFA date of July 11, 2026, for relacorilant in platinum-resistant ovarian cancer.
• Anticipate a likely EMA regulatory decision date in the fourth quarter of 2026 for relacorilant in platinum-resistant ovarian cancer.
• Continue to create new selective cortisol modulators and advance the most promising ones towards the clinic.
• Monitor and respond to ongoing legal proceedings, including the Teva Antitrust Litigation scheduled for trial in March 2027.

Key Dates

Recommendation

The filing presents a mixed bag of significant developments. While the strong performance of the oncology pipeline, particularly the positive ROSELLA trial results for relacorilant in ovarian cancer, and the continued revenue growth from Korlym are positive, the FDA's Complete Response Letter for relacorilant in hypercortisolism and the unfavorable outcome of the Teva patent litigation introduce substantial uncertainty and competitive pressure. The company's cash position is solid, but increased operating expenses led to a decline in net income. Given these conflicting signals, a "hold" recommendation is appropriate as investors await clarity on the relacorilant regulatory path for hypercortisolism and the full impact of generic competition and antitrust litigation.

Keywords

Corcept Therapeutics, CORT, Korlym, mifepristone, relacorilant, hypercortisolism, Cushing's syndrome, ovarian cancer, ALS, MASH, cortisol modulator, biopharmaceutical, clinical trials, FDA, NDA, EMA, MAA, oncology, endocrinology, metabolic diseases, neurology, drug development, specialty pharmacy, Curant Health, patent litigation, antitrust, SEC filing, 10-K